Cargando…

Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review

Specific drug therapy has been proven to improve functional capacity and slow disease progression in pulmonary arterial hypertension (PAH), regretfully with the data on the risk of respiratory tract infection (RTI) associated with specific drug therapy being limited. Databases of Medline, Embase, Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Zhichun, Zhang, Chi, Wei, Anhua, Cui, Min, Pu, Jun, Lin, Houwen, Liu, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701205/ https://www.ncbi.nlm.nih.gov/pubmed/29176655 http://dx.doi.org/10.1038/s41598-017-16349-7

Ejemplares similares

Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta‐Analysis of 4894 Patients From 24 Randomized Double‐Blind Placebo‐Controlled Clinical Trials
por: Wei, Anhua, et al.
Publicado: (2016)

Ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction: A case report
por: Zhang, Chi, et al.
Publicado: (2017)

Incident pulmonary arterial hypertension associated with Bosutinib
por: Yo, Shaun, et al.
Publicado: (2020)

Pulmonary arterial hypertension incidence in Latvia in 2019
por: Kaulins, Ricards, et al.
Publicado: (2022)

Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2020)

Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension
por: Riou, Marianne, et al.
Publicado: (2020)

New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023)

Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension
por: Chandel, Abhimanyu, et al.
Publicado: (2021)

Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2019)

Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study
por: Norell, Puck N., et al.
Publicado: (2022)

Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension
por: Alfraidi, Hassan, et al.
Publicado: (2018)

Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors
por: Gu, Li, et al.
Publicado: (2020)

Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension
por: Wu, Sheryl, et al.
Publicado: (2022)

QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter–defibrillator: Case report and review of the literature
por: Wei, Anhua, et al.
Publicado: (2017)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

Drug repositioning in pulmonary arterial hypertension: challenges and opportunities
por: Grinnan, Daniel, et al.
Publicado: (2019)

Pulmonary hypertensive crisis in children with pulmonary arterial hypertension undergoing cardiac catheterization
por: Li, Qiangqiang, et al.
Publicado: (2022)

Vital Roles of Gremlin‐1 in Pulmonary Arterial Hypertension Induced by Systemic‐to‐Pulmonary Shunts
por: Meng, Liukun, et al.
Publicado: (2020)

Perivascular Inflammation in Pulmonary Arterial Hypertension
por: Hu, Yijie, et al.
Publicado: (2020)

The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension
por: Zeng, Wei-Jie, et al.
Publicado: (2012)

How to select the appropriate candidate of pulmonary arterial hypertension: specific therapy in elderly patients with pulmonary hypertension
por: Yaylali, Yalin Tolga
Publicado: (2017)

Drugs that act on the respiratory tract
por: Yogaratnam, Dinesh, et al.
Publicado: (2021)

A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy
por: Ataya, Ali, et al.
Publicado: (2016)

Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact
por: Mercurio, Valentina, et al.
Publicado: (2018)

Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension
por: Morrisroe, Kathleen, et al.
Publicado: (2017)

Up-Regulated Lipocalin-2 in Pulmonary Hypertension Involving in Pulmonary Artery SMC Resistance to Apoptosis
por: Wang, Guoliang, et al.
Publicado: (2014)

Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
por: Alencar, Allan K. N., et al.
Publicado: (2017)

Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2017)

Network module‐based drug repositioning for pulmonary arterial hypertension
por: Wang, Rui‐Sheng, et al.
Publicado: (2021)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Pulmonary Arterial Hypertension
por: Michelakis, Evangelos D., et al.
Publicado: (2007)

Treatment of pulmonary hypertension in three patients with β-thalassemia intermedia using pulmonary arterial hypertension-specific medications
por: Gerede, Demet Menekşe, et al.
Publicado: (2016)

Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension
por: Xu, Zhuoyuan, et al.
Publicado: (2021)

Common genetic variants in pulmonary arterial hypertension
por: Gu, Sue, et al.
Publicado: (2018)

Pulmonary hypertension and pulmonary artery dissection
por: Corrêa, Ricardo de Amorim, et al.
Publicado: (2013)

Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?
por: Graham, Brian B., et al.
Publicado: (2023)

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

Incidence and outcomes of pulmonary hypertension in the Ireland
por: Cullivan, Sarah, et al.
Publicado: (2022)

An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension
por: Agnihotri, Vinit, et al.
Publicado: (2022)

Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?
por: Alamri, Ayedh K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dbvf244onlqlg3t54ub9c7l45s